Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist
Background CMP-001, also known as vidutolimod, is a virus-like particle containing a TLR9 agonist that is showing promise in early clinical trials. Our group previously demonstrated that the immunostimulatory effects of CMP-001 are dependent on an anti-Qβ antibody response which results in opsonizat...
Saved in:
| Main Authors: | George J Weiner, Aliasger K Salem, Shakoora A Sabree, Andrew P Voigt, Sue E Blackwell, Ajaykumar Vishwakarma, Michael S Chimenti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e002484.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
by: Zhaoming Wang, et al.
Published: (2020-10-01) -
The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis
by: Mohsin H. K. Roshan, et al.
Published: (2016-01-01) -
A Chemically Defined TLR3 Agonist with Anticancer Activity
by: Julie Le Naour, et al.
Published: (2023-12-01) -
De novo design of protein minibinder agonists of TLR3
by: Chloe S. Adams, et al.
Published: (2025-01-01) -
TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity
by: Shuting Wu, et al.
Published: (2025-01-01)